二季度，阿司利康的股价值得期盼。_老虎社区_美港股上老虎

二季度，阿司利康的股价值得期盼。

荒野求生
2017-03-26

$阿斯利康(AZN)$ 2016年的药物泰格瑞斯今年定会继续大放异彩，毕竟肺癌是癌症发病率最高的癌症，这款药优越性明显强于放化疗。2017年二季度有一款重磅新药Durvalumab要上市，同样值得期待。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

彭雯
·2018-07-11
6
回复
点赞
举报

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":51088,"tweetId":"51088","gmtCreate":1490494623580,"gmtModify":1704875911932,"author":{"id":59628406059810,"idStr":"59628406059810","authorId":59628406059810,"authorIdStr":"59628406059810","name":"荒野求生","avatar":"https://static.laohu8.com/106bc47351cc46a3171b1384ed02f5ce","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.laohu8.com/75be39b33b53d7fda2fd61da96347731"}],"coverImages":[{"img":"https://static.laohu8.com/75be39b33b53d7fda2fd61da96347731"}],"title":"二季度，阿司利康的股价值得期盼。","extraTitle":"","html":"<html><head></head><body><p>$阿斯利康(AZN)$ 2016年的药物泰格瑞斯今年定会继续大放异彩，毕竟肺癌是癌症发病率最高的癌症，这款药优越性明显强于放化疗。2017年二季度有一款重磅新药Durvalumab要上市，同样值得期待。</p> <img src=\"https://static.laohu8.com/75be39b33b53d7fda2fd61da96347731\"></body></html>","htmlText":"<html><head></head><body><p>$阿斯利康(AZN)$ 2016年的药物泰格瑞斯今年定会继续大放异彩，毕竟肺癌是癌症发病率最高的癌症，这款药优越性明显强于放化疗。2017年二季度有一款重磅新药Durvalumab要上市，同样值得期待。</p> <img src=\"https://static.laohu8.com/75be39b33b53d7fda2fd61da96347731\"></body></html>","text":"$阿斯利康(AZN)$ 2016年的药物泰格瑞斯今年定会继续大放异彩，毕竟肺癌是癌症发病率最高的癌症，这款药优越性明显强于放化疗。2017年二季度有一款重磅新药Durvalumab要上市，同样值得期待。","highlighted":1,"essential":1,"paper":2,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/51088","repostId":0,"isVote":1,"tweetType":1,"viewCount":4358,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["AZN"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":170,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":844742,"commentId":"844742","gmtCreate":1531314276653,"gmtModify":1531314276653,"authorId":3494396190619324,"author":{"id":3494396190619324,"idStr":"3494396190619324","authorId":3494396190619324,"name":"彭雯","avatar":"https://static.tigerbbs.com/7c23569579141f99c01722e796dd5726","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":51088,"objectIdStr":"51088","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"6","text":"6","html":"6","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}

二季度，阿司利康的股价值得期盼。

评论（1）

热议股票